DEPAKOTE (divalproex sodium) by AbbVie is tract. First approved in 1983.
Drug data last refreshed 21h ago · AI intelligence enriched 1w ago
DEPAKOTE (divalproex sodium) is an oral delayed-release anticonvulsant approved in 1983 that increases brain GABA concentrations to treat epilepsy and related seizure disorders. The exact mechanisms of its therapeutic effects remain incompletely understood, though GABA enhancement is the primary hypothesized pathway.
LOE-approaching product with moderate competitive pressure (30) suggests declining team investment and shift toward generic/lifecycle management roles rather than growth-focused positions.
tract. The mechanisms by which valproate exerts its therapeutic effects have not been established. It has been suggested that its activity in epilepsy is related to increased brain concentrations of gamma-aminobutyric acid (GABA).
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Bioequivalence Study of Divalproex Sodium ER Tablets 500 mg of Dr. Reddy's Under Fasting Conditions
Bioequivalence Study of Divalproex Sodium ER Tablets, 500 mg Under Fed Conditions
Quetiapine SR and Divalproex Sodium ER in the Treatment of Anxiety in Bipolar Disorder With Panic Disorder and/or GAD
Bioequivalence Study of Divalproex Sodium Capsules(Sprinkle),125 mg of Dr. Reddy's Under Fasting Condition (Apple Sauce)
Bioequivalence Study of Dr. Reddy's Divalproex Sodium Coated Particles in Capsules, 125 mg, Under Fed Condition
Worked on DEPAKOTE at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on DEPAKOTE offers limited growth trajectory and career visibility as the product approaches LOE with zero linked job openings. This role is better suited for professionals seeking to gain defensive brand management, competitive response, or generic transition experience rather than launch or growth expertise.